valeant pharmaceuticals international, inc. form 6-k

"With this approval," continued Mr. Melnyk, "we will accelerate our international licensing program and begin manufacturing product to fillinitial stocking programs for the fourth quarter of 1996. We expect early European sales to begin contributing to Biovail's sales and earnings bythe end of this year, with a much stronger impact in 1997 as more approvals are obtained and additional licensing agreements are reached." TheCompany is currently registering Tiazac(R) in the balance of the EC using the decentralized mutual recognition procedure, a process whichshould be completed by the fourth quarter of 1996.Mr. Melnyk concluded, "Forest Laboratories' aggressive rollout of Tiazac(R) in the U.S., initiated in late February, is being spearheaded byheavy promotion and advertising to physicians specializing in the treatment of hypertension. Our initial feedback is very positive; with newprescriptions being written and filled, a trend that we anticipate will escalate rapidly in subsequent quarters. To meet this growing demand, weare ramping up and expanding our production capabilities in Puerto Rico and Manitoba, Canada."Biovail Corporation International is an international full-service pharmaceutical company, engaged in the formulation, clinical testing,registration and manufacture of drug products utilizing advanced drug delivery technologies.###